Pharmaceutical

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the...

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer’s Disease in Japan

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...

Dipharma publishes a peer-reviewed study in Organic Process Research & Development: a novel approach to detect and characterize nitrosamine formation in APIs

The pioneer method combines the nitrosation assay procedure (NAP) with 15N-enriched nitrosating reagents and 15N NMR spectroscopy for a safer...

Thanksgiving Wishes to the DEA’s Anti Cannabis Holdouts – And Gently Suggests They Spend a Moment Thinking About Patients Waiting for Legal Medicine

MMJ Wishes DEA Officials a Happy Thanksgiving - While Reminding Them That Huntington's Chorea Doesn't Take Holidays. WASHINGTON, D.C. /...

Internet of Behaviors Market Surges to USD 14.3 Billion by 2033, Propelled by 26.5% CAGR – Verified Market Reports®

Internet of Behaviors (IoB) market projection signals robust CAGR driven by exponential data proliferation, AI-driven behavioral analytics and cross-channel orchestration....

In-Silico Clinical Trials Market Set to Reach USD 6.39 Billion by 2033 as Pharma and MedTech Accelerate Digital-First Validation, AI Modeling & Virtual Patient Simulations

AUSTIN, Texas and TOKYO, Nov. 27, 2025 /PRNewswire/ -- According to DataM Intelligence, the In-Silico Clinical Trials Market Size was...

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures

A non-invasive, AI-based, wearable earpiece that continuously monitors brain activity to enable the early detection of seizure risk in real...

error: Content is protected !!